GSK ratings under pressure with Tesaro buy, states Moody's
Moody’s has slapped a negative outlook on the UK’s GlaxoSmithKline, after the pharmaceuticals company said it planned a debt funded $5.1bn deal for US oncology company Tesaro.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts